Pre- and post-surgery treatment for HER2+ hepatoid stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment plan given before and after surgery for a rare type of stomach cancer called hepatoid adenocarcinoma. It's for people whose tumors have a specific HER2 protein marker and are at an early enough stage that surgery is still possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your stomach cancer must be the 'hepatoid adenocarcinoma' type.
- Your tumor must have a positive HER2 result (1+, 2+, or 3+ by IHC).
- Your cancer must be stage II or III (not stage I or IV).
- You need to be healthy enough for daily activities (ECOG score 0 or 1) and able to undergo surgery and the treatment before it.
- You cannot have had any other cancer treatment before joining this trial.
- Your tumor must not have a mismatch repair deficiency or high microsatellite instability.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment given before and after surgery for a rare type of stomach cancer called hepatoid adenocarcinoma. It aims to improve outcomes for patients whose tumors are HER2-negative and have not spread too far.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests a combination of three drugs after surgery for HER2-positive stomach cancer: an immunotherapy (serplulimab), a targeted therapy (trastuzumab), and chemotherapy (SOX). The goal is to see if this treatment helps prevent the cancer from coming back.
This Phase 2 trial tests adding chemotherapy plus trastuzumab and toripalimab around the time of surgery for HER2-positive, locally advanced stomach or esophagus-stomach junction cancer. It aims to shrink the cancer and reduce the chance it comes back by attacking it through more than one pathway.
This trial tests combining chemotherapy (FOLFOX) with an immunotherapy drug (Toripalimab) before and after surgery for a type of stomach cancer called HER2-negative adenocarcinoma of the esophagogastric junction. It may help shrink the tumor and improve outcomes.
This trial is testing a combination of four medicines (RC48, adebrelimab, apatinib, and S-1) as a pre-surgery treatment for people with locally advanced stomach cancer that is HER2 positive. The goal is to shrink the tumor before surgery and possibly improve outcomes.
Hear when a new Hepatoid Adenocarcinoma of Stomach trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.